Lawsuit Claims Anti-Depressant Company
Suppressed Drug's Addictive Nature
LOS ANGELES A lawsuit
contends the manufacturer of the popular anti-depressant Paxil
concealed evidence that the drug can be addictive.
The lawsuit was filed Friday on behalf of
35 people from around the country who say they suffered
symptoms ranging from electric-like shocks to suicidal
thoughts after discontinuing use of the drug.
The lawsuit, which seeks class-action
status and unspecified damages, says GlaxoSmithkline PLC
concealed the possibility of physical and psychological
withdrawal symptoms from the drug. It alleges fraud, deceit,
negligence, liability, and breach of warranty.
There was no immediate comment from the
British-based company. Calls to its U.S. offices after
business hours Friday were not returned.
Introduced on the U.S. market in 1992,
Paxil is the country's second-largest selling anti-depressant.
Paul Domb, 42, of Miami, said that after he
stopped taking Paxil last year, he suffered from convulsions,
night sweats, and suicidal thoughts for about six weeks.
He said he thought the problems had to do
with recent heart surgery, but after researching his symptoms
he concluded they were caused by his withdrawal from Paxil.
"I stopped taking this drug ... and it
destroyed me. It almost killed me," he said.
In June, a Wyoming jury awarded $8 million
in damages to the family of a man after determining that Paxil
caused him to kill his wife, daughter and granddaughter before